Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians

Background Apical Membrane Antigen 1 (AMA1) of Plasmodium falciparum merozoites is a leading blood-stage malaria vaccine candidate. Protection of Aotus monkeys after vaccination with AMA1 correlates with antibody responses. Study Design/Results A randomized, controlled, double-blind phase 1 clinical trial was conducted in 54 healthy Malian adults living in an area of intense seasonal malaria transmission to assess the safety and immunogenicity of the AMA1-C1 malaria vaccine. AMA1-C1 contains an equal mixture of yeast-expressed recombinant proteins based on sequences from the FVO and 3D7 clones of P. falciparum, adsorbed on Alhydrogel. The control vaccine was the hepatitis B vaccine (Recombivax). Participants were enrolled into 1 of 3 dose cohorts (n = 18 per cohort) and randomized 2∶1 to receive either AMA1-C1 or Recombivax. Participants in the first, second, and third cohorts randomized to receive AMA1-C1 were vaccinated with 5, 20 and 80 µg of AMA1-C1, respectively. Vaccinations were administered on days 0, 28, and 360, and participants were followed until 6 months after the final vaccination. AMA1-C1 was well tolerated; no vaccine-related severe or serious adverse events were observed. AMA1 antibody responses to the 80 µg dose increased rapidly from baseline levels by days 14 and 28 after the first vaccination and continued to increase after the second vaccination. After a peak 14 days following the second vaccination, antibody levels decreased to baseline levels one year later at the time of the third vaccination that induced little or no increase in antibody levels. Conclusions Although the AMA1-C1 vaccine candidate was well-tolerated and induced antibody responses to both vaccine and non-vaccine alleles, the antibody response after a third dose given at one year was lower than the response to the initial vaccinations. Additionally, post-vaccination increases in anti-AMA1 antibody levels were not associated with significant changes in in vitro growth inhibition of P. falciparum. Trial Registration ClinicalTrials.gov NCT00343005

[1]  J. Shiver,et al.  Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex , 2006, Proceedings of the National Academy of Sciences.

[2]  Hong Zhou,et al.  Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. , 2006, Vaccine.

[3]  M. Good,et al.  Memory B cell responses and malaria , 2006, Parasite immunology.

[4]  M. Good,et al.  Plasmodium yoelii Can Ablate Vaccine-Induced Long-Term Protection in Mice1 , 2005, The Journal of Immunology.

[5]  K. Bojang,et al.  Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. , 2005, Vaccine.

[6]  Hong Zhou,et al.  Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria , 2005, Infection and Immunity.

[7]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[8]  A. Dicko,et al.  The etiology of severe anemia in a village and a periurban area in Mali. , 2004, Blood.

[9]  A. Thomas,et al.  Apical Membrane Antigen 1, a Major Malaria Vaccine Candidate, Mediates the Close Attachment of Invasive Merozoites to Host Red Blood Cells , 2004, Infection and Immunity.

[10]  J. K. Moch,et al.  Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Siegrist.  Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. , 2003, Vaccine.

[12]  R. Anders,et al.  Geographical Structure of Diversity and Differences between Symptomatic and Asymptomatic Infections for Plasmodium falciparum Vaccine Candidate AMA1 , 2003, Infection and Immunity.

[13]  A. Saul,et al.  In Vitro Studies with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 (AMA1): Production and Activity of an AMA1 Vaccine and Generation of a Multiallelic Response , 2002, Infection and Immunity.

[14]  B. Keegan,et al.  Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria , 2002, Infection and Immunity.

[15]  S. Howell,et al.  Proteolytic Processing and Primary Structure ofPlasmodium falciparum Apical Membrane Antigen-1* , 2001, The Journal of Biological Chemistry.

[16]  D. Conway,et al.  Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. , 2001, Genetics.

[17]  R. Anders,et al.  Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.

[18]  T. Triglia,et al.  Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species , 2000, Molecular Microbiology.

[19]  D. Conway,et al.  Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. , 2000, Molecular and biochemical parasitology.

[20]  Huji Xu,et al.  CD4+ T Cells Acting Independently of Antibody Contribute to Protective Immunity to Plasmodium chabaudi Infection After Apical Membrane Antigen 1 Immunization1 , 2000, The Journal of Immunology.

[21]  A. Thomas,et al.  Immunization with Parasite-Derived Apical Membrane Antigen 1 or Passive Immunization with a Specific Monoclonal Antibody Protects BALB/c Mice against Lethal Plasmodium yoelii yoeliiYM Blood-Stage Infection , 2000, Infection and Immunity.

[22]  B. Greenwood,et al.  A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. , 1999, The American journal of tropical medicine and hygiene.

[23]  A. Thomas,et al.  Precise Timing of Expression of a Plasmodium falciparum-derived Transgene in Plasmodium berghei Is a Critical Determinant of Subsequent Subcellular Localization* , 1998, The Journal of Biological Chemistry.

[24]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[25]  R. Moritz,et al.  The Disulfide Bond Structure of Plasmodium Apical Membrane Antigen-1* , 1996, The Journal of Biological Chemistry.

[26]  R. Anders,et al.  Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes , 1996, Infection and immunity.

[27]  R. Coppel,et al.  Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum. , 1996, Molecular and biochemical parasitology.

[28]  B. Nahlen,et al.  Genetic conservation of the Plasmodium falciparum apical membrane antigen-1 (AMA-1). , 1996, Molecular and biochemical parasitology.

[29]  R. Coppel,et al.  Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. , 1994, The American journal of tropical medicine and hygiene.

[30]  C. Rogier,et al.  High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. , 1994, The American journal of tropical medicine and hygiene.

[31]  A. Thomas,et al.  Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. , 1994, Molecular and biochemical parasitology.

[32]  T. McCutchan,et al.  A merozoite receptor protein from Plasmodium knowlesi is highly conserved and distributed throughout Plasmodium. , 1990, The Journal of biological chemistry.

[33]  A. Waters,et al.  Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum. , 1990, Molecular and biochemical parasitology.

[34]  R. Anders,et al.  Plasmodium falciparum: two antigens of similar size are located in different compartments of the rhoptry. , 1990, Experimental parasitology.

[35]  F. Deinhardt,et al.  Vaccination against hepatitis B: comparison of three different vaccination schedules. , 1989, The Journal of infectious diseases.

[36]  R. Anders,et al.  Integral membrane protein located in the apical complex of Plasmodium falciparum , 1989, Molecular and cellular biology.

[37]  S. Hadler,et al.  Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. , 1989, Vaccine.

[38]  A. Waters,et al.  Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen , 1988, Parasite immunology.

[39]  W. Trager,et al.  Initial extracellular development in vitro of merozoites of Plasmodium falciparum. , 1984, The Journal of protozoology.

[40]  A. Thomas,et al.  The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. , 1984, Molecular and biochemical parasitology.

[41]  A. Thomas,et al.  Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. , 1982, Clinical and experimental immunology.

[42]  J. Cherry,et al.  Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. , 1981, Pediatrics.

[43]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[44]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[45]  M. Fay.  Random marginal agreement coefficients: rethinking the adjustment for chance when measuring agreement. , 2005, Biostatistics.

[46]  R. Anders,et al.  Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. , 1998, Vaccine.

[47]  D. Kaslow,et al.  Pathways and strategies for developing a malaria blood-stage vaccine. , 1998, Annual review of immunology.

[48]  H. Margolis,et al.  Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. , 1992, Current clinical topics in infectious diseases.